Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Puma and CANBridge cancel licensing deal for $20m
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
THE FACES OF BREAST CANCER
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Pierre Fabre & NERLYNX commercialisation | Nerlynx
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Partners of the Pierre Fabre Group: from health to beauty
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
Puma regains China rights to Nerlynx and amends deal with Fabre
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Puma Biotech Expands Pierre Fabre License to Add Countries
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Puma regains China rights to Nerlynx and amends deal with Fabre
Pierre Fabre engagements | NERLYNX
Puma regains China rights to Nerlynx and amends deal with Fabre
Accord entre Pierre Fabre et Puma Biotechnology
